
PATENT PATENT



**DOCKET NO.: UNGR-1632** 

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Evan C. Unger

Confirmation No.: 8641

**Application No.: 10/084,855** 

Group Art Unit: 1617

Filing Date: February 27, 2002

Examiner: Shaham J. Sharareh

For: NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS

DATE OF DEPOSIT: Chaques \$ 20, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,

VA 22313-1450.

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

s dellife	a iii 57 Cr K g 1.50(0).
	In accordance with § 1.97(b), since this Information Disclosure Statement is
	being filed either within three months of the filing date of the above-identified
00000015	application, within three months of the date of entry into the national stage of 10084855

01 FC:1806

08/25/2004 RMEBRAHT

180.00 OP

	the above identified ap	opplication as set forth in § 1.491, before the mailing date			
	of a first Office Action	on on the merits of the above-identified application, or			
	before the mailing da	te of a first Office Action after the filing of request for			
	continued examination	under § 1.114, no additional fee is required.			
	In accordance with §	1.129(a), this Information Disclosure Statement is being			
	filed in connection w	rith  the first or  second After Final Submission,			
	therefore:				
	☐ Certific	eation in Accordance with § 1.97(e) is attached; or			
	The fee	of <u>\$180.00</u> as set forth in § 1.17(p) is attached.			
$\boxtimes$	In accordance with §	1.97(c), this Information Disclosure Statement is being			
	filed after the period s	et forth in § 1.97(b) above but before the mailing date of			
	either a Final Action u	under § 1.113 or a Notice of Allowance under § 1.311, or			
	before an action that o	therwise closes prosecution in the application, therefore:			
		Certification in Accordance with § 1.97(e) is attached;			
		or			
	$\boxtimes$	The fee of $$180.00$ as set forth in § 1.17(p) is attached.			
	In accordance with §	1.97(d), this Information Disclosure Statement is being			
	filed after the mailing	date of either a Final Action under § 1.113 or a Notice			
	of Allowance under §	1.311 but before, or simultaneously with, the payment			
	of the Issue Fee, therefore included are: Certification in Accordance with §				
	1.97(e); and the submi	ssion fee of \$180.00 as set forth in § 1.17(p).			
$\boxtimes$	Copies of each of the	e references listed on the attached Form PTO-1449 are			
	enclosed herewith				

DOCKET NO	O.: UN	NGR-1632 - 3 -	PATENT
	Copie	s of references listed on the attached Form F	PTO-1449 are enclosed
	herew	rith	
	Copie	s of references listed on the attached Form PTO	1449 are not required to
	be sul	bmitted pursuant to the June 30, 2003 recent	revisions to 37 CFR §
	1.98(a	a)(2)(i).	
	EXCE	EPT THAT:	
		In view of the voluminous nature of reference	es [list as appropriate],
		and the likelihood that these references are available.	ailable to the Examiner,
		copies are not enclosed herewith.	
		In accordance with § 1.98(d), copies of the fol	lowing references listed
		on the attached Form PTO-1449 are not enc	losed herewith because
		they were previously cited by or submitted	to the U.S. Patent and
		Trademark Office in patent application(s) for w	hich a claim for priority
		under 35 U.S.C.§ 120 have been made in the in	stant application:
		Copies of references [list as appro	opriate] listed on the
		attached Form PTO-1449 were previous	sly cited by or submitted
		to the Patent and Trademark Office in	n prior Application No.
		, filed .	

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

DOCKET NO.: UNGR-1632

-4
PATENT

☐ The relevance of those listed references which are not in the English language is as follows:

☐ There are no listed references which are not in the English language.

☐ Alanguage

Date: 8/40/2004

Steven D. Maslowski
Registration No. 46,905

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2004 WW



Sheet 1 of 1

	585	Unger, E., et al., "Gas filled lipid bilayers as imaging contrast agents," J. of Liposome Res., 1994, 4(2), 861-874					
	505	Investigative Radiology, 29(Suppl. 2), S134-S136					
	584	vesicles (liposomes)," Ann. Rev. Biophy. Bioeng., 1980, 9, 467-508  Talsma, H., et al., "Liposomes as drug delivery systems, Part I: Preparation,"  Pharmaceutical Technology, 1992, 96-106					
	583						
	582	emulsions," J. of Parenteral Science & Technology, 1983, 37(4), 145-150					
	581 Hansrani, P.K., et al., "The preparation and properties of sterile intravenous						
	580	Goldberg, B.B., et al., "Ultrasound contrast agents: a review," <i>Ultrasound in Med. &amp; Biol.</i> , <b>1994</b> , <i>20(4)</i> , 319-333					
	ОТНЕ		uding Author, Title, Dat				
			Confirmation No. 5556				
		nent of Commerce Trademark Office	Filing Date February 27, 2002	Group 1617			
Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Applicant Evan C. Unger				
			Docket No. UNGR-1632	Application No. 10/084,855			